BACKGROUND: To date, limited options are available to treat malignant prostate cancer, and novel strategies need to be developed. Oncolytic viruses (OV) that have preferential replication capabilities in cancer cells rather than normal cells represent one promising alternative for treating malignant tumors. Vesicular stomatitis virus (VSV) is a non-segmented, negative-strand RNA virus with the inherent capability to selectively kill tumor cells. The aim of this study was to evaluate the potential of VSV-ΔM51-GFP as an effective therapeutic agent for treating prostate tumors. METHODS: For in vitro experiments, DU145 and PC3 cell lines were treated with VSV-ΔM51-GFP. Viral titers were quantified using plaque assays. Cytotoxicity was performed by MTT analysis. IFN-β production was measured using a Human IFN-β detection ELISA Kit. The detection of apoptosis was performed via Annexin-V-FITC staining method and analyzed with flow cytometry. The in vivo antitumor efficacy of VSV-ΔM51-GFP in a xenograft mice prostate tumor model. RESULTS: It was observed that VSV-ΔM51-GFP can efficiently replicate and lyse human prostate cancer cells and that this virus has reduced toxicity against normal human prostate epithelial cells in vitro. VSV-ΔM51-GFP in the induction of apoptosis in DU145 cells and PC3 cells. Furthermore, in a xenograft tumor animal model, nude mice bearing replication-competent VSV-ΔM51-GFP were able to eradicate malignant cells while leaving normal tissue relatively unaffected. The survival of the tumor-burdened animals treated with VSV-ΔM51-GFP may also be significantly prolonged compared to mock-infected animals. CONCLUSIONS: VSV-ΔM51-GFP showed promising oncolytic activity for treating prostate cancer.
BACKGROUND: To date, limited options are available to treat malignant prostate cancer, and novel strategies need to be developed. Oncolytic viruses (OV) that have preferential replication capabilities in cancer cells rather than normal cells represent one promising alternative for treating malignant tumors. Vesicular stomatitis virus (VSV) is a non-segmented, negative-strand RNA virus with the inherent capability to selectively kill tumor cells. The aim of this study was to evaluate the potential of VSV-ΔM51-GFP as an effective therapeutic agent for treating prostate tumors. METHODS: For in vitro experiments, DU145 and PC3 cell lines were treated with VSV-ΔM51-GFP. Viral titers were quantified using plaque assays. Cytotoxicity was performed by MTT analysis. IFN-β production was measured using a Human IFN-β detection ELISA Kit. The detection of apoptosis was performed via Annexin-V-FITC staining method and analyzed with flow cytometry. The in vivo antitumor efficacy of VSV-ΔM51-GFP in a xenograft miceprostate tumor model. RESULTS: It was observed that VSV-ΔM51-GFP can efficiently replicate and lyse humanprostate cancer cells and that this virus has reduced toxicity against normal human prostate epithelial cells in vitro. VSV-ΔM51-GFP in the induction of apoptosis in DU145 cells and PC3 cells. Furthermore, in a xenograft tumor animal model, nude mice bearing replication-competent VSV-ΔM51-GFP were able to eradicate malignant cells while leaving normal tissue relatively unaffected. The survival of the tumor-burdened animals treated with VSV-ΔM51-GFP may also be significantly prolonged compared to mock-infected animals. CONCLUSIONS:VSV-ΔM51-GFP showed promising oncolytic activity for treating prostate cancer.
Entities:
Keywords:
Vesicular stomatitis virus; oncolytic virotherapy; prostate cancer
Authors: Cleo Y F Lee; Luke X X Bu; Arrigo DeBenedetti; B Jill Williams; Paul S Rennie; William W G Jia Journal: Mol Ther Date: 2010-02-23 Impact factor: 11.454
Authors: Na Wei; Jun Kai Fan; Jin Fa Gu; Ling Feng He; Wen Hao Tang; Xin Cao; Xin Yuan Liu Journal: Biochem Biophys Res Commun Date: 2009-08-03 Impact factor: 3.575
Authors: L J Ausubel; M Meseck; I Derecho; P Lopez; C Knoblauch; R McMahon; J Anderson; N Dunphy; V Quezada; R Khan; P Huang; W Dang; M Luo; D Hsu; S L C Woo; L Couture Journal: Hum Gene Ther Date: 2011-03-08 Impact factor: 5.695
Authors: Guy Ungerechts; Christoph Springfeld; Marie E Frenzke; Johanna Lampe; William B Parker; Eric J Sorscher; Roberto Cattaneo Journal: Mol Ther Date: 2007-08-21 Impact factor: 11.454
Authors: Robert E Edge; Theresa J Falls; Christopher W Brown; Brian D Lichty; Harold Atkins; John C Bell Journal: Mol Ther Date: 2008-06-17 Impact factor: 11.454
Authors: J Altomonte; L Wu; M Meseck; L Chen; O Ebert; A Garcia-Sastre; J Fallon; J Mandeli; S L C Woo Journal: Cancer Gene Ther Date: 2008-10-10 Impact factor: 5.987
Authors: Carles Urbiola; Frédéric R Santer; Monika Petersson; Gabri van der Pluijm; Wolfgang Horninger; Patrik Erlmann; Guido Wollmann; Janine Kimpel; Zoran Culig; Dorothee von Laer Journal: Int J Cancer Date: 2018-07-03 Impact factor: 7.396
Authors: Matthew C Morris; Thomas M Russell; Cole A Lyman; Wesley K Wong; Gordon Broderick; Maureen C Ferran Journal: PLoS One Date: 2022-02-02 Impact factor: 3.240